Bertelmann, Thomas

[["dc.bibliographiccitation.firstpage","2271"],["dc.bibliographiccitation.issue","6"],["dc.bibliographiccitation.journal","Diabetes therapy"],["dc.bibliographiccitation.lastpage","2289"],["dc.bibliographiccitation.volume","9"],["dc.contributor.author","Ziemssen, Focke"],["dc.contributor.author","Wachtlin, Joachim"],["dc.contributor.author","Kuehlewein, Laura"],["dc.contributor.author","Gamulescu, Maria-Andreea"],["dc.contributor.author","Bertelmann, Thomas"],["dc.contributor.author","Feucht, Nikolaus"],["dc.contributor.author","Voegeler, Jessica"],["dc.contributor.author","Koch, Mirja"],["dc.contributor.author","Liakopoulos, Sandra"],["dc.contributor.author","Schmitz-Valckenberg, Steffen"],["dc.contributor.author","Spital, Georg"],["dc.date.accessioned","2020-12-10T14:14:40Z"],["dc.date.available","2020-12-10T14:14:40Z"],["dc.date.issued","2018"],["dc.identifier.doi","10.1007/s13300-018-0513-2"],["dc.identifier.eissn","1869-6961"],["dc.identifier.issn","1869-6953"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?gs-1/15572"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/71434"],["dc.language.iso","en"],["dc.notes.intern","DOI Import GROB-354"],["dc.notes.intern","Merged from goescholar"],["dc.rights","CC BY-NC 4.0"],["dc.rights.uri","https://creativecommons.org/licenses/by-nc/4.0"],["dc.title","Intravitreal Ranibizumab Therapy for Diabetic Macular Edema in Routine Practice: Two-Year Real-Life Data from a Non-interventional, Multicenter Study in Germany"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","271"],["dc.bibliographiccitation.issue","1"],["dc.bibliographiccitation.journal","Case reports in ophthalmology"],["dc.bibliographiccitation.lastpage","278"],["dc.bibliographiccitation.volume","8"],["dc.contributor.author","Bertelmann, Thomas"],["dc.contributor.author","Frank, Hans Ulrich"],["dc.contributor.author","Fuchs, Hendrik Ansgar"],["dc.contributor.author","Feltgen, Nicolas"],["dc.date.accessioned","2020-12-10T18:37:48Z"],["dc.date.available","2020-12-10T18:37:48Z"],["dc.date.issued","2017"],["dc.identifier.doi","10.1159/000475520"],["dc.identifier.eissn","1663-2699"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/77096"],["dc.language.iso","en"],["dc.notes.intern","DOI Import GROB-354"],["dc.title","Branch Retinal Vein Occlusion, Macular Ischemia, and Intravitreal Anti-VEGF Therapy"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","153"],["dc.bibliographiccitation.issue","02"],["dc.bibliographiccitation.journal","Klinische Monatsblätter für Augenheilkunde"],["dc.bibliographiccitation.lastpage","160"],["dc.bibliographiccitation.volume","238"],["dc.contributor.author","Bertelmann, Thomas"],["dc.contributor.author","Strempel, Ilse"],["dc.date.accessioned","2021-04-14T08:28:31Z"],["dc.date.available","2021-04-14T08:28:31Z"],["dc.date.issued","2021"],["dc.identifier.doi","10.1055/a-1244-6242"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/82633"],["dc.language.iso","de"],["dc.notes.intern","DOI Import GROB-399"],["dc.relation.eissn","1439-3999"],["dc.relation.issn","0023-2165"],["dc.title","Psychotherapeutic Treatment Options in Glaucoma Patients"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.artnumber","7"],["dc.bibliographiccitation.issue","1"],["dc.bibliographiccitation.journal","BMC Ophthalmology"],["dc.bibliographiccitation.volume","17"],["dc.contributor.author","Ziemssen, F."],["dc.contributor.author","Feltgen, N."],["dc.contributor.author","Holz, FG."],["dc.contributor.author","Guthoff, R."],["dc.contributor.author","Ringwald, A."],["dc.contributor.author","Bertelmann, T."],["dc.contributor.author","Wiedon, A."],["dc.contributor.author","Korb, C."],["dc.date.accessioned","2019-07-09T11:43:05Z"],["dc.date.available","2019-07-09T11:43:05Z"],["dc.date.issued","2017"],["dc.description.abstract","Abstract Background While randomized controlled trials (RCTs) are based on strict inclusion/exclusion criteria, non-interventional studies (NISs) might provide additional information to guide management in patients more representative to the real-world setting. The aim of this study was to compare baseline characteristics of patients receiving intravitreal treatment in the NIS OCEAN with those from published RCTs. Methods The ongoing OCEAN study enrolled patients treated with ranibizumab for neovascular age-related macular degeneration (nAMD), diabetic macular oedema (DME) or branch/central retinal vein occlusion (B/CRVO). Baseline patient characteristics were compared by indication within the OCEAN cohort. Furthermore, the characteristics were set in reference to those of published RCTs in the same indications. Confidence intervals (CIs) were calculated and assessed for statistically significant differences as indicated by non-overlapping CIs. Results Patient characteristics in the NIS OCEAN were evaluated for 3,614 patients with nAMD, 1,211 with DME, 204 with BRVO and 121 with CRVO. Between these groups, significant differences in mean age, gender distributions, and mean baseline VA were seen, reflecting known differences between the indications. Compared to the patient characteristics of published RCTs (trials selected by literature search: nAMD: 13 RCTs, DME: 9, RVO: 5), the OCEAN patients’ mean age was significantly higher in every indication. The gender distributions across the trials were comparable, with only few differences between OCEAN and the RCTs. Regarding the mean baseline VA, notable differences were found in nAMD and in DME, with VA significantly higher in some RCTs and lower in others. Conclusions The described differences underline the complementarity of NISs and RCTs. OCEAN covers a broader spectrum and more variability of patients than do RCTs. As baseline values may have impact on the treatment response (ceiling effect), there is an ongoing need for research in all patient subgroups. Country-specific assessments of patient populations can better reflect the real-world situation. NISs can deliver insights that RCTs may not, as NISs can include non-typical patients, patients with comorbidities, a broader age spectrum and patients of various disease stages. Trial registration The NIS OCEAN was registered on www.clinicaltrials.gov (identifier: NCT02194803 )."],["dc.identifier.doi","10.1186/s12886-017-0401-y"],["dc.identifier.pmid","28103831"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?gs-1/14161"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/58822"],["dc.language.iso","en"],["dc.notes.intern","Merged from goescholar"],["dc.publisher","BioMed Central"],["dc.rights","CC BY 4.0"],["dc.rights.uri","https://creativecommons.org/licenses/by/4.0"],["dc.title","Demographics of patients receiving Intravitreal anti-VEGF treatment in real-world practice: healthcare research data versus randomized controlled trials"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","604"],["dc.bibliographiccitation.issue","5"],["dc.bibliographiccitation.journal","Current Eye Research"],["dc.bibliographiccitation.lastpage","614"],["dc.bibliographiccitation.volume","45"],["dc.contributor.author","Pielen, Amelie"],["dc.contributor.author","Feltgen, Nicolas"],["dc.contributor.author","Hattenbach, Lars-Olof"],["dc.contributor.author","Hoerauf, Hans"],["dc.contributor.author","Bertelmann, Thomas"],["dc.contributor.author","Quiering, Claudia"],["dc.contributor.author","Vögeler, Jessica"],["dc.contributor.author","Priglinger, Siegfried"],["dc.contributor.author","Lang, Gabriele E."],["dc.contributor.author","Schmitz-Valckenberg, Steffen"],["dc.contributor.author","Wolf, Armin"],["dc.contributor.author","Rehak, Matus"],["dc.date.accessioned","2021-04-14T08:26:42Z"],["dc.date.available","2021-04-14T08:26:42Z"],["dc.date.issued","2019"],["dc.identifier.doi","10.1080/02713683.2019.1679839"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/82046"],["dc.language.iso","en"],["dc.notes.intern","DOI Import GROB-399"],["dc.relation.eissn","1460-2202"],["dc.relation.issn","0271-3683"],["dc.title","Ranibizumab Pro Re nata versus Dexamethasone in the Management of Ischemic Retinal Vein Occlusion: Post-hoc Analysis from the COMRADE Trials"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","e933"],["dc.bibliographiccitation.issue","8"],["dc.bibliographiccitation.journal","Acta Ophthalmologica"],["dc.bibliographiccitation.lastpage","e941"],["dc.bibliographiccitation.volume","96"],["dc.contributor.author","Feltgen, Nicolas"],["dc.contributor.author","Hattenbach, Lars-Olof"],["dc.contributor.author","Bertelmann, Thomas"],["dc.contributor.author","Callizo, Josep"],["dc.contributor.author","Rehak, Matus"],["dc.contributor.author","Wolf, Armin"],["dc.contributor.author","Berk, Hüsnü"],["dc.contributor.author","Eter, Nicole"],["dc.contributor.author","Lang, Gabriele E."],["dc.contributor.author","Pielen, Amelie"],["dc.contributor.author","Schmitz-Valckenberg, Steffen"],["dc.contributor.author","Quiering, Claudia"],["dc.contributor.author","Rose, Uwe"],["dc.contributor.author","Hoerauf, Hans"],["dc.date.accessioned","2020-12-10T18:26:52Z"],["dc.date.available","2020-12-10T18:26:52Z"],["dc.date.issued","2018"],["dc.identifier.doi","10.1111/aos.13770"],["dc.identifier.issn","1755-375X"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/76197"],["dc.language.iso","en"],["dc.notes.intern","DOI Import GROB-354"],["dc.title","Comparison of ranibizumab versus dexamethasone for macular oedema following retinal vein occlusion: 1-year results of the COMRADE extension study"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","2485"],["dc.bibliographiccitation.issue","12"],["dc.bibliographiccitation.journal","Graefe's Archive for Clinical and Experimental Ophthalmology"],["dc.bibliographiccitation.lastpage","2485"],["dc.bibliographiccitation.volume","256"],["dc.contributor.author","Paul, C."],["dc.contributor.author","Bertelmann, T."],["dc.contributor.author","Schumann, R. G."],["dc.date.accessioned","2020-12-10T14:10:34Z"],["dc.date.available","2020-12-10T14:10:34Z"],["dc.date.issued","2018"],["dc.identifier.doi","10.1007/s00417-018-4114-6"],["dc.identifier.eissn","1435-702X"],["dc.identifier.issn","0721-832X"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/70804"],["dc.language.iso","en"],["dc.notes.intern","DOI Import GROB-354"],["dc.title","Letter of response to “Comment re: Comparison of the horizontal diameter to a modeled area of traction in eyes with vitreomacular traction: is the diameter close enough to the truth?”"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.artnumber","e0270120"],["dc.bibliographiccitation.issue","7"],["dc.bibliographiccitation.journal","PLOS ONE"],["dc.bibliographiccitation.volume","17"],["dc.contributor.author","Paul, Christoph"],["dc.contributor.author","Müller, Hans-Helge"],["dc.contributor.author","Raber, Thomas"],["dc.contributor.author","Bertelmann, Thomas"],["dc.contributor.authorgroup","on behalf of the EXPORT study group"],["dc.contributor.editor","Wang, I-Jong"],["dc.date.accessioned","2022-09-01T09:51:00Z"],["dc.date.available","2022-09-01T09:51:00Z"],["dc.date.issued","2022"],["dc.description.abstract","Purpose\r\n To evaluate a multivariable model predicting the individual probability of successful intravitreal ocriplasmin (IVO) treatment in eyes with vitreomacular traction (VMT).\r\n \r\n \r\n Methods\r\n Data from three prospective, multicenter IVO studies (OASIS, ORBIT, and INJECT) were pooled. Patients were included if they were treated for a symptomatic VMT without a full-thickness macular hole. A prediction model for VMT resolution using the factors ‘age’ and ‘horizontal VMT diameter’ was validated by receiver operating characteristic analysis and according to grouped prediction after calibration. Multivariable regression analysis was performed to check robustness and explore further improvements.\r\n \r\n \r\n Results\r\n Data from 591 eyes was included. In the univariate analysis all key factors (age, gender, VMT diameter, lens status, ERM) significantly correlated to treatment success. The prediction model was robust and clinically applicable to estimate the success rate of IVO treatment (AUC of ROC: 0.70). A refinement of the model was achieved through a calibration process.\r\n \r\n \r\n Conclusion\r\n The developed multivariable model using ‘horizontal VMT diameter’ and ‘age’ is a valid tool for prediction of VMT resolution upon IVO treatment."],["dc.identifier.doi","10.1371/journal.pone.0270120"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/113855"],["dc.language.iso","en"],["dc.notes.intern","DOI-Import GROB-597"],["dc.relation.eissn","1932-6203"],["dc.rights.uri","http://creativecommons.org/licenses/by/4.0/"],["dc.title","Calculating the individual probability of successful ocriplasmin treatment in eyes with vitreomacular traction–Validation and refinement of a multivariable prediction model"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.artnumber","132"],["dc.bibliographiccitation.journal","Health and Quality of Life Outcomes"],["dc.bibliographiccitation.volume","14"],["dc.contributor.author","Bertelmann, Thomas"],["dc.contributor.author","Feltgen, Nicolas"],["dc.contributor.author","Scheffler, Martin"],["dc.contributor.author","Hufenbach, Ulrich"],["dc.contributor.author","Wiedon, Annette"],["dc.contributor.author","Wilhelm, Helmut"],["dc.contributor.author","Ziemssen, Focke"],["dc.date.accessioned","2018-11-07T10:08:27Z"],["dc.date.available","2018-11-07T10:08:27Z"],["dc.date.issued","2016"],["dc.description.abstract","Background: Vision-related quality of life (vrQoL) is advancing more and more into the focus of interest in ophthalmological clinical research. However, to date only little information is available about vrQoL from large non-interventional studies in terms of \"real-world evidence\". The purpose of this investigation was to describe baseline VFQ-25 visual function scores, to evaluate whether they differ from previous phase III clinical trials, to determine which contributing factors (e.g. indication, age, gender) affect VFQ-25 scores and to identify its impact on driving. Methods: The non-interventional OCEAN study (Observation of treatment patterns with LuCEntis and real life ophthalmic monitoring, including optional OCT in Approved iNdications) is the largest ophthalmic study conducted in Germany, to evaluate the real world situation of patients treated with ranibizumab (NCT02194803). The NEI-VFQ-25 questionnaire was conducted at baseline, months 4, 12 and 24. Descriptive statistics was used to analyse the baseline data. ANOVA was performed to evaluate the impact of various contributing factors on composite and selected subscale scores. Results: Overall, 4844 (84.1 %) of all 5760 OCEAN patients completed the VFQ-25 questionnaire at baseline. Thereof, 3414 treatment-naive patients were further analysed. Overall, the VFQ subscore general health was most affected by the ocular disease, followed by general vision. No major differences were detected in comparison to corresponding VFQ-25 scores of previous phase III clinical trials, except in DME patients, or with respect to possible contributing factors. A tendency towards a more decreased VFQ-25 composite score was observed for nAMD, for elderly patients >= 75 years of age, for female patients, for patients with low baseline visual acuity (VA; <50 letters) and for those with statutory health insurance. Indication, age, gender, baseline VA (all p <0.01) and the interaction of age and indication, as well as baseline VA and indication (p <0.01 each) had a significant impact on composite, general vision and distance vision scores (ANOVA). About 10 % of patients gave up driving due to eyesight issues. Conclusions: The knowledge of a patient's subjective disease burden is crucial to understanding anxieties and mental anguish. Additionally, the understanding of the impact of various contributing factors on the VFQ-25 scores and the extent to which they can be influenced help to optimize patient care. It demonstrates the need for medical and mental support by all medical staff, to encourage patients' compliance with a comprehensive anti-VEGF therapy, to increase BCVA and, consecutively, VFQ-25 scores."],["dc.description.sponsorship","Novartis Pharma GmbH, Germany"],["dc.identifier.doi","10.1186/s12955-016-0536-1"],["dc.identifier.isi","000384693800001"],["dc.identifier.pmid","27644469"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?gs-1/13885"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/39464"],["dc.notes.intern","Merged from goescholar"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Biomed Central Ltd"],["dc.relation.issn","1477-7525"],["dc.rights","CC BY 4.0"],["dc.rights.uri","https://creativecommons.org/licenses/by/4.0"],["dc.title","Vision-related quality of life in patients receiving intravitreal ranibizumab injections in routine clinical practice: baseline data from the German OCEAN study"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","1092"],["dc.bibliographiccitation.issue","8"],["dc.bibliographiccitation.journal","British Journal of Ophthalmology"],["dc.bibliographiccitation.lastpage","1097"],["dc.bibliographiccitation.volume","102"],["dc.contributor.author","Paul, Christoph"],["dc.contributor.author","Heun, Christine"],["dc.contributor.author","Müller, Hans-Helge"],["dc.contributor.author","Hoerauf, Hans"],["dc.contributor.author","Feltgen, Nicolas"],["dc.contributor.author","Wachtlin, Joachim"],["dc.contributor.author","Kaymak, Hakan"],["dc.contributor.author","Mennel, Stefan"],["dc.contributor.author","Koss, Michael Janusz"],["dc.contributor.author","Fauser, Sascha"],["dc.contributor.author","Maier, Mathias M"],["dc.contributor.author","Schumann, Ricarda G"],["dc.contributor.author","Mueller, Simone"],["dc.contributor.author","Chang, Petrus"],["dc.contributor.author","Schmitz-Valckenberg, Steffen"],["dc.contributor.author","Kazerounian, Sara"],["dc.contributor.author","Szurman, Peter"],["dc.contributor.author","Lommatzsch, Albrecht"],["dc.contributor.author","Bertelmann, Thomas"],["dc.date.accessioned","2020-12-10T18:37:12Z"],["dc.date.available","2020-12-10T18:37:12Z"],["dc.date.issued","2018"],["dc.identifier.doi","10.1136/bjophthalmol-2017-310874"],["dc.identifier.eissn","1468-2079"],["dc.identifier.issn","0007-1161"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/76873"],["dc.language.iso","en"],["dc.notes.intern","DOI Import GROB-354"],["dc.title","Calculating the individual probability of successful ocriplasmin treatment in eyes with VMT syndrome: a multivariable prediction model from the EXPORT study"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dspace.entity.type","Publication"]]